CTLA4 and hypophysitis: Thyroid dysfunction occurs in up to 20% of patients receiving PD-1 or programmed death-ligand 1 (PD-L1) inhibitors [2], while hypophysitis is more commonly seen with CTLA-4 inhibitors, affecting approximately 10% of treated individuals [1].